Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression
- 1 August 2003
- journal article
- Published by Elsevier in Gastroenterology
- Vol. 125 (2) , 544-555
- https://doi.org/10.1016/s0016-5085(03)00896-5
Abstract
No abstract availableKeywords
This publication has 61 references indexed in Scilit:
- Hypertriglyceridemia as a Cardiovascular Risk FactorPublished by Elsevier ,1998
- Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertriglyceridemia is not mediated by effects on apolipoprotein E.Journal of Clinical Investigation, 1997
- Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles.Journal of Clinical Investigation, 1992
- Hypertriglyceridemia as a Result of Human apo CII Gene Expression in Transgenic MiceScience, 1990
- Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.Journal of Clinical Investigation, 1986
- Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.Journal of Clinical Investigation, 1985
- Apolipoprotein C-II and C-III levels in hyperlipoproteinemiaMetabolism, 1979
- HYPERTRIGLYCERIDÆMIA ASSOCIATED WITH AN ABNORMAL TRIGLYCERIDE-RICH LIPOPROTEIN CARRYING EXCESS APOLIPOPROTEIN C-III-2The Lancet, 1979
- Effect of serum and C‐apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipaseFEBS Letters, 1976
- Serum Triglycerides in Coronary Artery DiseaseArchives of internal medicine (1960), 1959